Hexacath France received the Prix Galien 2021 in the “Medical Device” category with TiTAN OPTiMAX indicated in the treatment of coronary syndromes

Before committing to the development of new technologies, Hexacath relied on a large body of pre-clinical evidence and fundamental in vitro and in vivo studies.

Over almost 2 decades have been necessary to gather an impressive amount of clinical evidence demonstrating the Titan bioactive stent Superiority in ACS drug-eluting stent in Acute Coronary Syndrome patients and the interest of the continuous thermodilution technology using the RayFlow microcatheter to assess Coronary Microvascular Disease.